Angiogenesis Completed Phase 2 Trials for Melphalan (DB01042)

IndicationStatusPhase
DBCOND0036757 (Angiogenesis)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00744536Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDSTreatment